# Multimodal Imaging in Rectal Cancer & Pancreatic Cancer

> **NCT06395337** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Rectal Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** [111In]In-DOTA-ANTI-CEA antibody injection
- **RADIATION:** SPECT/CT scan
- **PROCEDURE:** Resection surgery

## Key facts

- **NCT ID:** NCT06395337
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-02
- **Primary completion:** 2025-05-02
- **Final completion:** 2025-06-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395337, "Multimodal Imaging in Rectal Cancer & Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06395337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*